The pharmaceutical sector faced fresh turbulence following President Trump’s announcement to cut drug prices. Novo Nordisk, heavily reliant on US sales, finds itself among the biggest losers in early European trading. Investors are concerned about how price cuts may affect the profitability of large pharmaceutical firms. This shift in policy could significantly alter the landscape for pharmaceutical companies and investors alike. Keeping track of these developments is essential for understanding market behaviors. Stakeholders must prepare for a potential restructuring of drug pricing and its widespread implications in the industry.